Market Place
Sourcing Support
IASO Bio Presents CAR T-Cell Persistence Study for Myeloma
09 Dec 2024 //
PR NEWSWIRE
JAMA Publishes IASO Bio`s Equecabtagene Autoleucel MM Data
07 Nov 2024 //
PR NEWSWIRE
IASO Bio & Chinese Physicians to cooperate for Cancer Treatment
30 Sep 2024 //
PR NEWSWIRE
IASO Bio Presented Clinical Outcomes On Lymphodepletion Prior
29 Sep 2024 //
PR NEWSWIRE
IASO Bio Presented Outcomes Of R/RMM Patients At IMS Meeting
27 Sep 2024 //
PR NEWSWIRE
FDA approves IASO Bio’s IND for equecabtagene autoleucel
12 Aug 2024 //
PHARMACEUTICAL TECHNOLOGY
IASO Bio`s IASO-782 IND Approved For Systemic Lupus Erythematosus
25 Jul 2024 //
PR NEWSWIRE
Innovent Biologics & IASO Bio enter strategic collaboration in cell therapy
08 Jul 2024 //
PHARMABIZ
IASO Bio Presents Clinical Data On Equecabtagene Autoleucel At EAN Congress 2024
01 Jul 2024 //
PR NEWSWIRE
IASO`s GPRC5D CAR-T RD118 Receives IND Approval From NMPA For Multiple Myeloma
28 Jun 2024 //
PR NEWSWIRE
IASO Bio Presents FUCASO Data In New MM At EHA 2024
15 Jun 2024 //
PR NEWSWIRE
IASO Single-Cell Omics On Autoimmune CNS Therapy In Science
10 May 2024 //
PR NEWSWIRE
IASO Bio Announces FDA Approval of IND Application for BCMA CAR-T for GMG
03 Apr 2024 //
PR NEWSWIRE
IASO NMPA`s IND Approval for Equecabtagene Autoleucel for Treatment of Myeloma
29 Mar 2024 //
PR NEWSWIRE
IASO BIO Announces New Development Partnership with Umoja Biopharma
03 Jan 2024 //
PR NEWSWIRE
IASO Bio and Innovent Present New Data of FUCASO for Multiple Myeloma
11 Dec 2023 //
PR NEWSWIRE
IASO Bio Establishes International CAR-T Diagnostic
20 Nov 2023 //
BUSINESSWIRE
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO
28 Sep 2023 //
PR NEWSWIRE
Innovent and IASO Bio Present Updated Data for BCMA CAR-T FUCASO
28 Sep 2023 //
PR NEWSWIRE
China approves BCMA CAR-T therapy for multiple myeloma
03 Jul 2023 //
ENDPTS
IASO & Innovent Announce the NMPA Approval of NDA for Equecabtagene Autoleucel
02 Jul 2023 //
PR NEWSWIRE
IASO Bio Receives FDA Approval of IND Application for IASO-782
17 Jun 2023 //
PR NEWSWIRE
IASO Bio & Innovent Updated Efficacy and Safety Data of Equecabtagene Autoleucel
05 Jun 2023 //
PR NEWSWIRE
IASO Bio Announces CT103A Granted RMAT and Fast Track Designations by the FDA
12 Feb 2023 //
PR NEWSWIRE
IASO Bio Raises Nearly $75 Million in Series C1 Funding
17 Jan 2023 //
PR NEWSWIRE
U.S. FDA Approves Trial Application for IASO Bio`s BCMA CAR-T CT103A
22 Dec 2022 //
PRNEWSWIRE
Umoja and IASO partner to develop therapies for haematological malignancies
22 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
IASO & Cabaletta Announce License Agreement for Clinically Validated CD19 Binder
11 Oct 2022 //
PRNEWSWIRE
IASO Biotherapeutics` Equecabtagene Autoleucel, Receives IND Approval by NMPA
19 Aug 2022 //
PRNEWSWIRE
IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy
12 Jun 2022 //
PRNEWSWIRE
IASO Bio, Innovent Announce NMPA Acceptance of NDA for Equecabtagene Autoleucel
02 Jun 2022 //
PRNEWSWIRE
IASO Bio`s Nanjing Mfg. Facility Licensed for CAR-T Cell Therapies
03 Mar 2022 //
CONTRACT PHARMA
FDA Grants ODD to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio & Innovent
13 Feb 2022 //
PRNEWSWIRE
Sana Biotechn, IASO and Innovent Announce Non-Exclusive License Agreement
10 Jan 2022 //
PRNEWSWIRE
IASO, Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy
11 Dec 2021 //
PRNEWSWIRE
IASO Biotheraputics` CT120 Granted Orphan Drug Designation by the U.S. FDA
26 Nov 2021 //
PRNEWSWIRE
IASO and Innovent to Present New BCMA CAR-T Cell Therapy Data at ASH 2021
10 Nov 2021 //
PRNEWSWIRE
IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer
19 Oct 2021 //
BUSINESSWIRE
China`s IASO nets $108M to advance cell therapies, antibodies
16 Sep 2021 //
FIERCEBIOTECH
IASO Biotherapeutics Secures $108M Series C Funding in Innovative Cell Therapies
16 Sep 2021 //
BUSINESSWIRE
IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T
18 Aug 2021 //
BUSINESSWIRE
IASO Biotherapeutics’ CD19/CD22 CAR-T Drug Receives Two IND Clearances
02 Aug 2021 //
BUSINESS WIRE
